VIA
AERI

Vantage Investment Advisors’s Aerie Pharmaceuticals AERI Stock Holding History

Vantage Investment Advisors’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-500
Closed -$10K – 805
2014
Q3 		$10K Buy
+500
New +$9.86K 0.01% 475

Other funds holding AERI

CV
Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Vantage Investment Advisors's AERI Position: Q4 2014 in Review

Vantage Investment Advisors sold out of Aerie Pharmaceuticals (AERI) in Q4 2014, closing a stake of 500 shares — an estimated $10K sold.

Vantage Investment Advisors first reported a position in AERI in Q3 2014 and held it in 1 quarter. The position peaked at $10K in Q3 2014. 98 funds tracked by Wall St. Rank hold AERI as of Q4 2014.

  • Vantage Investment Advisors reported no remaining Aerie Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • Vantage Investment Advisors sold 500 Aerie Pharmaceuticals shares in Q4 2014, an estimated $10K.
  • Vantage Investment Advisors first reported a position in Aerie Pharmaceuticals in Q3 2014 and held it in 1 quarter.
  • Vantage Investment Advisors's Aerie Pharmaceuticals position peaked at $10K in Q3 2014.
  • 98 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2014.

Based on Vantage Investment Advisors's 13F filing for Q4 2014, filed 4 Feb 2015.